| |JUNE 20268TOP STORIESINDIA CLEARS WOCKHARDT'S ZAYNICH FOR DRUG-RESISTANT INFECTIONSTATA-BACKED MEDTHERAPY CLAIMS CAR-T BREAKTHROUGH IN ONE DAYINDIA PHARMA MOVES ON ESG BUT FACES WASTE, ENERGY HURDLESP&G HEALTH STOCK SURGES 18% ON STRONG Q4 PROFIT GROWTHIndia has taken a significant step in addressing the growing threat of antimicrobial resistance, with the national drug regulator granting approval to Wockhardt's novel antibiotic Zaynich (Zidebactam/Cefepime).The therapy has been cleared for marketing and import to treat complicated urinary tract infections (cUTI), including severe kidney infections (pyelonephritis) and cases involving Gram-negative bloodstream infections in adult patients.The approval marks a major milestone for India's pharmaceutical innovation landscape, as Zaynich is an indigenously discovered and developed, first-in-class antibiotic designed to tackle some of the most challenging drug-resistant infections. PO Tata-backed MedTherapy claims a CAR-T breakthrough, marking what could be a major shift in cancer treatment manufacturing.According to the ICRA ESG Ratings report, India's pharmaceutical sector is entering a decisive phase where sustainability is no longer a marginal initiative but a core competitiveness factor shaped by global regulatory pressure and export market expectations.The sector has made visible progress in renewable energy adoption, with The company says it can now produce CAR-T therapy within just 24 hours, compared to the several weeks the process usually takes. If successful at scale, the development could help lower treatment costs and improve access to one of the most expensive forms of cancer care available today.CAR-T therapy is a personalised treatment used mainly for blood cancer treatment, where a patient's immune cells are modified to recognise and destroy cancer cells. The process involves collecting T-cells from the patient, genetically engineering them in a laboratory, and then reinfusing them into the body to fight the disease.However, despite its promise, CAR-T treatment remains difficult to access because production often takes four to eight weeks and comes at a very high cost. PO Procter & Gamble Health's strong stock rally following its March quarter results is not just a reaction to numbers, it reflects how the market is re-rating focused healthcare plays that are executing well across brand, supply chain, and margin expansion.The stock surged over 18% intraday to Rs 6,700 on the NSE, before settling around Rs 6,267--still up roughly 11% from the previous close of Rs 5,652.5. This movement stands in contrast to the broader market, with the Nifty50 remaining largely flat during the same period.usage rising from 17% in FY2023 to 25% in FY2025, signaling a gradual shift toward cleaner energy procurement models such as open access and group captive systems. This transition has helped moderate emission intensity, particularly among formulation players that recorded nearly 30% reduction.However, the broader efficiency narrative remains mixed. Energy intensity per unit of revenue has increased, largely due to pricing pressures and evolving product mix, indicating that cost dynamics are diluting sustainability gains. PO
< Page 7 | Page 9 >